Want to see NDRA full AI Analyst Report?
ENDRA Life Sciences (NDRA) AI Stock Analysis
ENDRA Life Sciences
(NASDAQ:NDRA)
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, and significant cash burn) and the limited usefulness of valuation metrics with a negative P/E. Partially offsetting this, technicals show an improving uptrend with neutral-to-positive momentum, while corporate events are mixed—greater deal/financing flexibility but continued Nasdaq monitoring risk.
ENDRA Life Sciences (NDRA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.12M
- Dividend Yield
- ―
- Average Volume (3M)
- 31.16K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.81
- Revenue Growth
- ―
- EPS Growth
- 98.17%
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
ENDRA Life Sciences Business Overview & Revenue Model
Company Description
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal b...
How the Company Makes Money
ENDRA’s revenue model is based primarily on commercializing its imaging technology and related products/services. Key expected/targeted revenue streams include: (1) System sales (capital equipment): selling TAEUS-based imaging systems to hospitals, i...
ENDRA Life Sciences Earnings Call Summary
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.
ENDRA Life Sciences Financial Statement Overview
Summary
Fundamentals remain highly speculative: revenue is consistently $0 while losses and cash burn are substantial (TTM net loss ~-$5.9M; operating cash flow ~-$4.8M; free cash flow ~-$7.8M). Balance-sheet leverage is modest (low debt), but equity volatility and deeply negative returns reflect ongoing funding risk despite narrowing losses.
Income Statement
8Very NegativeBalance Sheet
46NeutralCash Flow
12Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -39.72K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -7.40M | -6.87M | -11.30M | -9.78M | -12.92M | -11.01M |
| Net Income | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
Balance Sheet | ||||||
| Total Assets | 7.94M | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M |
| Cash, Cash Equivalents and Short-Term Investments | 1.74M | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M |
| Total Debt | 429.27K | 492.35K | 754.14K | 394.40K | 546.63K | 796.09K |
| Total Liabilities | 1.63M | 1.59M | 1.89M | 1.10M | 2.07M | 2.09M |
| Stockholders Equity | 6.31M | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
Cash Flow | ||||||
| Free Cash Flow | -7.84M | -5.20M | -7.42M | -9.58M | -12.97M | -11.17M |
| Operating Cash Flow | -4.82M | -5.18M | -7.40M | -9.55M | -12.77M | -11.12M |
| Investing Cash Flow | -332.89K | -3.02M | -12.80K | -24.72K | -202.58K | -45.00K |
| Financing Cash Flow | 8.89M | 5.73M | 7.81M | 7.52M | 8.40M | 13.40M |
ENDRA Life Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NDRA, the sentiment is Negative. The current price of 5.00 is below the 20-day moving average (MA) of 5.11, below the 50-day MA of 5.43, and above the 200-day MA of 4.80, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 61.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NDRA.
ENDRA Life Sciences Risk Analysis
ENDRA Life Sciences disclosed 46 risk factors in its most recent earnings report. ENDRA Life Sciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksENDRA Life Sciences Peers Comparison
Overall Rating
- NDRA51Neutral
BNBX47Neutral
ISPC41Neutral
INBS31Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NDRA | 51Neutral | $7.12M | -0.75 | -224.80% | ― | ― | 98.17% |
| BNBX | 47Neutral | $573.24K | -0.00 | -337.10% | ― | -27.39% | 99.29% |
| ISPC | 41Neutral | $2.08M | -0.02 | -524.37% | ― | -92.11% | 86.78% |
| INBS | 31Underperform | $5.84M | -0.19 | -170.36% | ― | 38.09% | 54.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NDRA | Endra Life Sciences | 4.80 | -0.19 | -3.81% | |
| BNBX | Bnb Plus Corp. | 0.09 | -3.32 | -97.45% | |
| INBS | Intelligent Bio Solutions Inc. | 1.66 | -6.77 | -80.31% | |
| ISPC | Ispecimen Inc | 0.83 | -25.21 | -96.80% | |
| BGLC | Bionexus Gene Lab Corporation | 1.00 | -4.31 | -81.09% |
ENDRA Life Sciences Corporate Events
ENDRA Life Sciences Amends Merger Agreement and Warrants
PositiveOn October 1, 2026, ENDRA Life Sciences and its merger partners executed a first amendment to their June 25, 2026 merger agreement, revising governance, financing and closing conditions for the planned combination. The amendment removes the requireme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026